A highly crystallizable T4 lysozyme (T4L) was fused to the N-terminus of the b 2 adrenergic receptor (b 2 AR), a G-protein coupled receptor (GPCR) for catecholamines. We demonstrate that the N-terminal fused T4L is sufficiently rigid relative to the receptor to facilitate crystallogenesis without thermostabilizing mutations or the use of a stabilizing antibody, G protein, or protein fused to the 3rd intracellular loop. This approach adds to the protein engineering strategies that enable crystallographic studies of GPCRs alone or in complex with a signaling partner.
Introduction
Obtaining well-diffracting crystals of G-protein coupled receptors remains one of the most challenging obstacles for structural studies of this important family of signaling proteins. Only a limited number of GPCR structures have been determined by xray crystallography. A factor contributing to the difficulty in obtaining GPCR crystals is the relatively small amount of polar surface area available for forming crystal lattice contacts.
We previously developed two strategies to address this problem. First, a stabilizing antibody was used to facilitate the crystallization of human beta2 adrenergic receptor (b 2 AR) [1] , and more recently to stabilize and crystallize the active state of the b 2 AR [2] . These antibodies bind and stabilize the cytoplasmic ends of transmembrane segments (TM) 5 and 6, and provide a structured hydrophilic surface for crystal packing interactions. In the second approach, T4 lysozyme (T4L) was fused to the cytoplasmic ends of TM5 and TM6, replacing the unstructured intracellular loop 3 (ICL3) [3] . The fused T4L formed packing interactions in the crystal lattice and resulted 2.4 Å crystal structure. Importantly, the TM5-T4L-TM6 fusion approach has been effective for at least seven other GPCRs [4] , [5] , [6] , [7] , [8] , [9] , [10] .
Although both of the strategies have been effective for crystallizing isolated GPCRs, neither can be used to facilitate crystallization of signaling complexes such as GPCR-G protein and GPCR-arrestin complexes, where the antibody or the fused T4L would interfere with complex formation. We therefore explored the use of T4L insertions on the extracellular surface of the b 2 AR. The extracellular loops of the b 2 AR and other GPCRs do not tolerate large insertions or deletions. In contrast, the amino terminus of the b 2 AR can be deleted without loss of function. We therefore chose to replace the N terminus of the b 2 AR with T4 lysozyme (T4L-GPCR fusion).
Results

Fusion of a T4L to the N-terminus of b 2 AR
To have a T4L-b 2 AR fusion protein suitable for crystallization, the link between T4L and the receptor must be short and relatively rigid, yet not interfere with receptor function. Several different fusion proteins were generated and examined for expression levels and binding properties (Fig. 1) . In an effort to generate a rigid interaction between T4L and the b 2 AR, we removed the relatively flexible C-terminus of the T4L and attempted to fuse the remaining C terminal helix of T4L with the extracellular end of TM1 of the b 2 AR. None of these constructs gave sufficient amounts of functional receptor.
In a second approach, we fused the carboxyl terminus of T4L to D29, the first amino acid of the extracellular helical extension of TM1. Four constructs were generated and examined: direct fusion of T4L to D29, and the inclusion of 1-3 Ala residues between T4L and the b 2 AR (Fig. 1) . The highest level of expression was obtained from the fusion with a two-Ala linker. The fusion protein had normal pharmacology and G protein coupling. To improve expression, two additional point mutations M96T and M98T were made in the b 2 AR component of the fusion protein. We have previously observed that mutation of these residues, which are located in the first extracellular loop and face away from the protein, had no effect on receptor function, but enhanced expression by up to two-fold. We were able to produce 1.5mg of pure, functional protein from 1 liter of Sf9 cells (Expression Systems, Woodland, CA).
The role of the N-T4L in facilitating crystallogenesis
The above version of T4L-b 2 AR was recently used to obtain the crystal structure of the b 2 AR-Gs complex [11] . However, in this structure most of the lattice contacts in this crystal are mediated by Gs, and the N terminal fused T4L does not interact with the extracellular surface of its fused b 2 AR (Fig. 2) . The lack of interactions between T4L and the extracellular surface of the b 2 AR in the b 2 AR-Gs complex suggested that T4L fused to the N terminus of the b 2 AR might not be sufficiently constrained to facilitate crystallogenesis in the absence of the cytoplasmic G protein. We therefore sought to determine if the amino terminal T4L could facilitate crystallogenesis in the absence of a soluble protein bound or fused to the third intracellular loop. Additional modifications were made to minimize unstructured sequence in the third intracellular loop and carboxyl terminus (Fig. 1) . We truncated the C-terminal residues after amino acid 365. The 3 rd intracellular loop (ICL3) of b 2 AR is another flexible region and it is subject to proteolysis [1] . This loop was truncated in the fusion protein by removing residues 235 to 263. The final construct T4L-b 2 AR-D-ICL3 is illustrated in Figure 1 .
To determine the functional integrity of T4L-b 2 AR-D-ICL3, we determined agonist and antagonist binding affinities. The ligand binding pocket is formed by amino acids from four transmembrane domains and is therefore very sensitive to any perturbation of the receptor structure. T4L-b 2 AR-D-ICL3 exhibits ligand binding affinities for the antagonist [3H]-Dihydroalprenolol and the agonist isopreterenol that are comparable to those of the wild type receptor (Fig. 3) . T4L-b 2 AR-D-ICL3 also maintains the ability to couple to the G-protein Gs (Fig. 3C) . The inhibition of basal GTPcS binding by the inverse agonist ICI-118551 is slightly greater for T4L-b 2 AR-D-ICL3 than for the wild-type b 2 AR. This observation suggests that the modifications used in constructing T4L-b 2 AR-D-ICL3 might lead to constitutive activity; however, the observed difference is not statistically significant and T4L- b 2 AR-D-ICL3 does not exhibit higher affinity for agonists (Fig. 3B) , a property often associated with constitutive activity in GPCRs.
Purified T4L-b 2 AR-D-ICL3 bound to the inverse agonist carazolol crystallized as small rods in lipid cubic phase (37% PEG300 (v/v), 0.1M Bis-Tris propane, pH 6.5, 0.1 M ammonium phosphate). Crystals diffracted to a resolution of 3.3 Å ; however, due to radiation damage, our dataset was limited to 4.0 (Table 1) . Nevertheless, the dataset allowed us to solve the structure by molecular replacement. The interaction between the b 2 AR and T4L is sufficiently rigid to detect electron density for the 2 Ala link between these two proteins (Fig. 4) . This link was not detectable in the electron density map of the b 2 AR-Gs structure [11] (Fig. 2 ). In the T4L-b 2 AR-D-ICL3 crystal lattice, the packing interactions are primarily mediated by T4L and there are no contacts between adjacent receptors ( The slightly lower value for T4L-b 2 AR-D-ICL3 is due to more extensive packing interactions between T4L and the receptor. Only minor differences can be observed in these two structures, presumably due to different crystal packing patterns. The similarity of the structures determined independently through different strategies further validates the fusion protein approach, demonstrating that structural distortions due to protein engineering or crystal packing are unlikely.
Of interest, ICL2 in the two inactive structures of b 2 AR-Fab5 and b 2 AR-T4L is in an extended loop while it is an alpha helix in both active structures: the b 2 AR-Gs complex [11] and the b 2 AR stabilized by Nb80 [2] . In both of the inactive structures (b 2 ARFab5 and b 2 AR-T4L), ICL2 participates in lattice contacts that may influence its conformation. However, in the T4L-b 2 AR-D-ICL3 structure ICL2 is not involved in packing interactions, yet is an extended loop that is nearly identical to that observed in the other inactive state b 2 AR structures (Fig. 6) . Thus, this extended loop structure may reflect an inactive state.
Discussion
The majority part of a G-protein coupled receptor is surrounded by lipids or detergents, allowing very limited hydrophilic surface for crystal packing contacts. It has been shown that increasing the hydrophilic surface at the cytoplasmic side of the receptor can facilitate GPCR crystallization. However, insertion of T4L or binding of an antibody to ICL3 prevents GPCRs from forming signaling complexes with cytosolic protein partners. As an alternative strategy, we used an amino terminal T4L fusion to increase the extracellular hydrophilic surface available for forming crystal lattice contacts. Our initial efforts to generate antibodies that recognize the extracellular surface of the b 2 AR were not successful. However, even if they were successful, these antibodies could not be used for other GPCRs. In contrast, the N-T4L fusion strategy may be more broadly applicable to other GPCRs and other membrane proteins. Our results demonstrate that the signal peptide used was sufficient to facilitate translocation of T4L domain across the endoplasmic reticulum membrane, ensuring proper orientation of TM1. Although it may compromise the rigidity of the fusion protein, a relatively flexible linker may be necessary to allow the receptor and the T4L to fold correctly. The optimal length of the linker between T4L and the amino terminus may differ for different GPCRs.
Compared with our previous strategies that utilized T4L or an antibody at the cytoplasmic surface, the N-terminal T4L fusion strategy allows for interactions between the b 2 AR and signaling and regulatory proteins as demonstrated by the recent b 2 AR-Gs complex structure. This approach also offers a protein engineering alternative for GPCRs and other membrane proteins that do not tolerate insertion of T4L or other hydrophilic proteins in cytoplasmic loops.
In conclusion, fusion of T4L to the amino terminus of a GPCR can facilitate crystallogenesis. This approach can also facilitate the formation of crystals of a GPCR in complex with a cytoplasmic signaling protein.
Materials and Methods
Generation of N-T4L fused b2AR constructs
The human b 2 AR in the pFastbac1 Sf9 expression vector truncated at amino acid 365 in the cytoplasmic tail (b 2 AR365) [1] was used as the starting template for generating the N-T4L fused b 2 AR constructs. The HA signal peptide followed by a FLAG epitope tag and a tobacco etch virus (TEV) protease recognition sequence were added to the N-terminus of the receptor to facilitate expression and purification. A point mutation of N187E was also introduced in the second extracellular loop to remove a glycosylation site (Fig. 1) .
DNA cassettes encoding two different versions of T4L lysozyme (full length or with truncated C-terminus) with different numbers of additional alanines attached to the C-terminus were generated and amplified by PCR using the original b 2 AR-T4L [3] as the template and synthetic oligonucleotides as primers. These different cassettes were inserted into the b 2 AR365 construct between the end of the TEV protease recognition sequence and Asp29, Glu30 or Val31 of the receptor as shown in (Fig. 1 ) by using the Quickchange multi protocol (Stratagene). Two point mutations M96T, M98T were also introduced into the b 2 AR sequence. Residues from Ser235 to Lys263 in the third intracellular loop were deleted with the Quickchange multi protocol using synthetic oligonucleotides as mutation primers. All the constructs were confirmed by DNA sequencing. The protein sequence of T4L- 
CWLPFFIVNIVHVIQDNLIRKEVYILLNWIGYVNSGFNPL-IYCRSPDFRIAFQELLCLRRSSLKAYGNGYSSNGNTGEQ-SG
(the HA signal peptide is shown in italic letters; the FLAG epitope tag is shown in letters with underscore; the TEV recognition sequence is marked with a box and the cleavage site is shown with an asterisk; the full length T4L is shown in orange; the b 2 AR sequence from Asp29 to Gly365 excluding Ser235 to K263 is shown in cyan, the 2-Ala linker is shown in blue).
The entire T4L-b 2 AR-D-ICL3 gene described above was further cloned into the Best-Bac Sf9 expression vector pvl1393 (Expression Systems, Woodland, CA) using the restriction enzyme 
GTPcS binding assay
The T4L-b 2 AR-D-ICL3 or the wild type b 2 AR was reconstituted in HDL particles (receptor?rHDL) as described by Whorton et al [13] . The Gs heterotrimer (Gas, his6-b1, c2) was expressed in Sf9 cells and purified as described by Kozasa et al [14] . In order to obtain reconstituted Gs-receptor?rHDL complex, the purified Gs was added into preformed receptor?rHDL at a molar ratio of 10:1 (the concentration of the Gs stock was high such that the contained detergent was diluted for about 1000 fold to a concentration well below its critical micelle concentration). In each GTPcS binding reaction, the above described Gs-receptor?rHDL mixture was preincubated with different ligands (no ligand, 10 mM of ICI-118551, or 10 mM of isoproterenol, respectively; the final concentration of the Gs is 1 nM and the receptor?rHDL is 0.1 nM) in 500 ml of buffer (75 mM Tris, 12.5 mM MgCl 2 , 1 mM EDTA, pH 7.4, supplemented with 0.5 mg/ml BSA) for 10 min Expression and purification of T4L-b 2 AR-D-ICL3 from baculovirus-infected Sf9 cells
Recombinant baculovirus was made from pvl1393-T4L-b 2 AR-D-ICL3 using Best-Bac expression system, as described by the system protocol (Expression Systems). T4L-b 2 AR-D-ICL3 was expressed by infecting Sf9 cells at a density of 4 million/ml with a second passage baculovirus stock using 1 ml of virus stock per 50 ml of cell culture. 1 mM of the antagonist alprenolol was included to enhance the receptor stability and yield. The infected cells were harvested after 48 hs of incubation at 27uC.
Cell pellets were lysed by vigorous stirring in lysis buffer (10 mM TRIS-Cl pH 7.5, 2 mM EDTA, 10 ml of buffer per gram of cell pellet) supplemented with protease inhibitor Leupeptin (2.5 mg/ml final concentration, Sigma) and Benzamindine (160 mg/ml final concentration, Sigma) for 15 minutes. The T4L-b 2 AR-D-ICL3 protein was extracted from the cell membrane by dounce homogenization in solubilization buffer (100 mM NaCl, 20 mM TRIS-Cl, pH 7.5, 1% Dodecylmaltoside) supplemented with Leupeptin and Benzamindine (2.5 mg/ml and 160 mg/ml final concentration, respectively). 10 ml of solubilization buffer was used for each gram of cell pellet. The Dodecylmaltoside (DDM)-solubilized T4L-b 2 AR-D-ICL3 bearing the FLAG epitope was then purified by M1 antibody affinity chromatography (Sigma). Extensive washing using HLS buffer (100 mM NaCl, 20 mM HEPES pH 7.5, 0.1%DDM) was performed to remove alprenolol. The protein was then eluted with HLS buffer containing a saturating concentration of cholesterol hemisuccinate (CHS) and supplemented with 5 mM EDTA and 200 mg/ml free FLAG peptide. The HLS-CHS buffer was prepared by mixing HLS with 0.05% (weight:volume) CHS for 1 hr at room followed by filtration through a 0.2 m filter to remove undissolved CHS.
The eluted T4L-b 2 AR-D-ICL3 was further purified by affinity chromatography using alprenolol-Sepharose as previously described [3] in order to isolate functional T4L-b 2 AR-D-ICL3 from non-functional protein. HHS buffer (350 mM NaCl, 20 mM HEPES pH 7.5, 0.1%DDM) supplemented with 300 mM alprenolol and a saturating concentration of CHS (prepared as above) was used to elute the protein. The eluted T4L-b 2 AR-D-ICL3 bound with alprenolol was then re-applied to M1 resin, allowing exchange of alprenolol with carazolol in HHS buffer supplemented with 30 nM carazolol. T4L-b 2 AR-D-ICL3 bound with carazolol was then eluted from M1 resin with HHS buffer supplemented with 5 mM EDTA, 200 mg/ml free FLAG peptide and saturating concentration of CHS (prepared as described above). The FLAG epitope tag of T4L-b 2 AR-D-ICL3 was removed by the treatment of tobacco etch virus (TEV) protease (Invitrogen) for 3 h at room temperature or overnight at 4uC. The untagged T4L-b 2 AR-D-ICL3-cazazolol complex was then further purified by size-exclusion chromatography (SEC) using an S200 column (GE healthcare) equilibrated in 100 mM NaCl, 10 mM HEPES pH 7.5, 0.1% DDM and 1 nM carazolol. The same buffer was used as the running buffer for SEC. The purity of the final T4L-b 2 AR-DICL3 is better than 90%, as assessed by SDS-PAGE.
Crystallization of the T4L-b 2 AR-DICL3-carazolol complex
The purified T4L-b 2 AR-D-ICL3-carazolol complex was concentrated to a final concentration of 60 mg/ml using centricon Vivaspin (GE healthcare). The complex was crystallized using the lipid cubic phase (LCP) method as previously described [8] . The protein complex was mixed with lipid moloolein with a 1:1.5 mass ratio at room temperature. 0.03 ml of the protein-lipid mixture drop was deposited in each well of a 96-well glass sandwich plate (Molecular Dimensions). The drop was then overlaid with 0.65 ml of precipitant and the well was sealed by glass coverslip. By using this method, the T4L-b 2 AR-D-ICL3-carazolol complex was crystallized in 37% PEG300 (v/v), 0.1 M Bis-Tris propane, pH 6.5, 0.1 M ammonium phosphate after 2 days of incubation in 20uC.
Data collection and structure determination
Crystals were harvested and frozen in liquid nitrogen directly without using additional cryo-protectant. Diffraction data from 15 different crystals were measured using the GM/CA-CAT minibeam at 23-ID-D, Advance Photon Source, Argonne National Labs. The data were processed with HKL2000 [15] and the structure solved by molecular replacement using Molrep. Further model rebuilding was performed by using Coot [16] and the structure was refined with Phenix [17] . The validation of the final structural model was performed using Molprobity [18] . Data processing and refinement statistics are shown in Table 1 . The root mean square deviaion value of 0.32 was calculated using pymol. The cutoff value is 3 and 268 out of 282 Ca atoms of the two structures (4GBR and 2RH1) were included in the structural alignment. Solvent accessible surface area calculation was also performed using Pymol.
